Business
Microbix Presenting at Muskoka Capital Event
MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, O...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix Presenting at Muskoka Capital EventMeetings with Growth-Oriented Investors, September 26 to 28, 2025\n\n\n\n MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (\n \n TSX: MBX, OTCQX: MBXBF, Microbix®\n \n ), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 26 to 28, 2025.\n \n\n Microbix’s CEO, Cameron Groome, and COO, Ken Hughes, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the event. The presentation slides to which they will be speaking will be posted to the Microbix website at https://microbix.com, along with other business information and its financial disclosures.\n \n\n\n About Microbix Biosystems Inc.\n \n\n Microbix creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) supporting POCT & clinical lab EQA, enabling assay development and validation, or helping ensure the quality of clinical diagnostic workflows. Its antigens drive the tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.\n \n\n Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headqua...